Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Centene Corporation stock logo
CNC
Centene
$33.06
-0.8%
$55.40
$32.99
$80.59
$16.58B0.445.51 million shs22.98 million shs
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
$10.16
-0.9%
$10.72
$8.49
$11.42
$46.07B0.259.50 million shs13.86 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$545.56
-0.3%
$512.86
$356.14
$579.02
$43.99B1.54643,573 shs448,551 shs
Seagen Inc. stock logo
SGEN
Seagen
$228.74
$228.74
$123.77
$228.96
$42.93B0.321.48 million shs86 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Centene Corporation stock logo
CNC
Centene
-0.65%-39.03%-40.07%-47.01%-50.19%
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
-1.88%-1.93%-8.22%+8.72%+19.95%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
-0.14%+1.72%+3.93%+51.11%+12.26%
Seagen Inc. stock logo
SGEN
Seagen
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Centene Corporation stock logo
CNC
Centene
4.9692 of 5 stars
4.23.00.03.72.21.74.4
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
2.6265 of 5 stars
2.43.02.50.01.90.01.9
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
3.7971 of 5 stars
1.44.00.03.73.52.51.3
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Centene Corporation stock logo
CNC
Centene
2.41
Hold$68.87108.31% Upside
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
2.73
Moderate Buy$12.3321.31% Upside
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.80
Moderate Buy$558.112.30% Upside
Seagen Inc. stock logo
SGEN
Seagen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest IDXX, CNC, SGEN, and HLN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Centene Corporation stock logo
CNC
Centene
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$65.00 ➝ $52.00
7/2/2025
Centene Corporation stock logo
CNC
Centene
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$65.00 ➝ $45.00
7/2/2025
Centene Corporation stock logo
CNC
Centene
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$90.00 ➝ $65.00
7/2/2025
Centene Corporation stock logo
CNC
Centene
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral$75.00 ➝ $48.00
7/2/2025
Centene Corporation stock logo
CNC
Centene
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$80.00 ➝ $45.00
7/2/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$510.00 ➝ $540.00
7/1/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$625.00
6/11/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$515.00 ➝ $580.00
6/9/2025
Centene Corporation stock logo
CNC
Centene
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$70.00
6/2/2025
Centene Corporation stock logo
CNC
Centene
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$84.00 ➝ $65.00
5/27/2025
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Centene Corporation stock logo
CNC
Centene
$169.28B0.10$9.81 per share3.37$52.49 per share0.63
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
$14.35B3.18$0.49 per share20.56$4.58 per share2.22
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.93B11.16$12.40 per share44.01$19.48 per share28.01
Seagen Inc. stock logo
SGEN
Seagen
$2.30B18.66N/AN/A$15.10 per share15.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Centene Corporation stock logo
CNC
Centene
$3.31B$6.714.934.490.452.04%14.56%4.75%7/25/2025 (Estimated)
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
$1.84B$0.3926.0520.732.9212.86%17.65%8.58%8/7/2025 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$887.87M$10.8250.4240.173.9922.76%57.35%26.97%8/4/2025 (Confirmed)
Seagen Inc. stock logo
SGEN
Seagen
-$610.31M-$4.01N/AN/AN/A-32.61%-28.06%-20.92%N/A

Latest IDXX, CNC, SGEN, and HLN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.28N/AN/AN/A$1.06 billionN/A
7/25/2025Q2 2025
Centene Corporation stock logo
CNC
Centene
$2.07N/AN/AN/A$44.71 billionN/A
5/1/2025Q1 2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$2.93$2.96+$0.03$2.96$998.25 million$998.43 million
4/25/2025Q1 2025
Centene Corporation stock logo
CNC
Centene
$2.52$2.90+$0.38$2.63$43.16 billion$46.62 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Centene Corporation stock logo
CNC
Centene
N/AN/AN/AN/AN/A
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
$0.252.46%N/A64.10%N/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Centene Corporation stock logo
CNC
Centene
0.65
1.11
1.11
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
0.53
0.98
0.78
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.31
1.16
0.81
Seagen Inc. stock logo
SGEN
Seagen
N/A
2.67
2.12

Institutional Ownership

CompanyInstitutional Ownership
Centene Corporation stock logo
CNC
Centene
93.63%
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
6.67%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%
Seagen Inc. stock logo
SGEN
Seagen
84.26%

Insider Ownership

CompanyInsider Ownership
Centene Corporation stock logo
CNC
Centene
0.36%
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
N/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.98%
Seagen Inc. stock logo
SGEN
Seagen
25.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Centene Corporation stock logo
CNC
Centene
60,500497.60 million495.81 millionOptionable
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
24,5614.49 billionN/ANot Optionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00080.42 million79.63 millionOptionable
Seagen Inc. stock logo
SGEN
Seagen
3,256187.70 million139.08 millionOptionable

Recent News About These Companies

Merck in "advanced talks" for $40bn Seagen bid; report
Seagen posts breast cancer win ahead of Pfizer takeover
Is Merck planning a $30bn-plus move for Seagen?
Pfizer raises guidance as COVID franchise drives Q3 beat
Franklin Biotechnology Discovery C
Seagen wins Enhertu patent dispute with Daiichi Sankyo
Pfizer: Turning The Corner (Rating Upgrade)
HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn
MRNA Feb 2024 64.000 put
MRNA Feb 2024 77.000 call
MRNA Feb 2024 67.000 put

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Centene stock logo

Centene NYSE:CNC

$33.06 -0.25 (-0.75%)
Closing price 07/7/2025 03:59 PM Eastern
Extended Trading
$33.12 +0.06 (+0.20%)
As of 07:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.

Haleon stock logo

Haleon NYSE:HLN

$10.16 -0.09 (-0.88%)
Closing price 07/7/2025 03:59 PM Eastern
Extended Trading
$10.08 -0.08 (-0.79%)
As of 07:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$545.56 -1.45 (-0.27%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$574.00 +28.44 (+5.21%)
As of 07:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Seagen stock logo

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.